HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells

Experimental Cell Research

Volumn 316, Issue 12, 2010, Pages 1985-1993

  Liu, Junye ^a   Zhang, Jing ^a   Wang, Xiaowu ^a   Li, Yan ^a   Chen, Yongbin ^a   Li, Kangchu ^a   Zhang, Jian ^a   Yao, Libo ^a   Guo, Guozhen ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; HIF 1; Hypoxia; NDRG2; Radioresistance

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MEMBRANE PROTEIN; N MYC DOWNSTREAM REGULATED PROTEIN 2; PROTEIN BAX; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; UTERINE CERVIX CANCER;

EID: 77953360484     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.02.028     Document Type: Article

References (40)

1. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
2. Moeller B.J., Richardson R.A., Dewhirst M.W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007, 26:241-248.
3. Adams J.M., Difazio L.T., Rolandelli R.H., Luján J.J., Haskó G., Csóka B., Selmeczy Z., Németh Z.H. HIF-1: a key mediator in hypoxia. Acta Physiol. Hung. 2009, 96:19-28.
4. Moeller B.J., Dewhirst M.W. HIF-1 and tumour radiosensitivity. Br. J. Cancer 2006, 95:1-5.
5. Markowska J., Grabowski J.P., Tomaszewska K., Kojs Z., Pudelek J., Skrzypczak M., Sobotkowski J., Emerich J., Olejek A., Filas V. Significance of hypoxia in uterine cervical cancer. Multicentre study. Eur. J. Gynaecol. Oncol. 2007, 28:386-388.
6. Dellas K., Bache M., Pigorsch S.U., Taubert H., Kappler M., Holzapfel D., Zorn E., Holzhausen H.J., Haensgen G. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther. Onkol. 2008, 184:169-174.
7. Yao L., Zhang J., Liu X. NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40:625-635.
8. Zhou R.H., Kokame K., Tsukamoto Y., Yutani C., Kato H., Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 2001, 73:86-97.
9. Zhang J., Li F., Liu X., Shen L., Liu J., Su J., Zhang W., Deng Y., Wang L., Liu N., Han W., Zhang J., Ji S., Yang A., Han H., Yao L. The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J. Biol. Chem. 2006, 281:39159-39168.
10. Deng Y., Yao L., Chau L., Ng S.S., Peng Y., Liu X., Au W.S., Wang J., Li F., Ji S., Han H., Nie X., Li Q., Kung H.F., Leung S.Y., Lin M.C. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int. J. Cancer 2003, 106:342-347.
11. Tepel M., Roerig P., Wolter M., Gutmann D.H., Perry A., Reifenberger G., Riemenschneider M.J. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int. J. Cancer 2008, 123:2080-2086.
12. Lusis E.A., Watson M.A., Chicoine M.R., Lyman M., Roerig P., Reifenberger G., Gutmann D.H., Perry A. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005, 65:7121-7126.
13. Lorentzen A., Vogel L.K., Lewinsky R.H., Saebø M., Skjelbred C.F., Godiksen S., Hoff G., Tveit K.M., Lothe I.M., Ikdahl T., Kure E.H., Mitchelmore C. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 2007, 7:192.
14. Piepoli A., Cotugno R., Merla G., Gentile A., Augello B., Quitadamo M., Merla A., Panza A., Carella M., Maglietta R., D'Addabbo A., Ancona N., Fusilli S., Perri F., Andriulli A. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med. Genomics 2009, 2:11.
15. Kim Y.J., Yoon S.Y., Kim J.T., Song E.Y., Lee H.G., Son H.J., Kim S.Y., Cho D., Choi I., Kim J.H., Kim J.W. NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis 2009, 30:598-605.
16. Shi H., Jin H., Chu D., Wang W., Zhang J., Chen C., Xu C., Fan D., Yao L. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol. Pharm. Bull. 2009, 32:968-975.
17. Choi S.C., Yoon S.R., Park Y.P., Song E.Y., Kim J.W., Kim W.H., Yang Y., Lim J.S., Lee H.G. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp. Mol. Med. 2007, 39:705-714.
18. Liu N., Wang L., Liu X., Yang Q., Zhang J., Zhang W., Wu Y., Shen L., Zhang Y., Yang A., Han H., Zhang J., Yao L. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem. Biophys. Res. Commun. 2007, 358:164-169.
19. Zhao H., Zhang J., Lu J., He X., Chen C., Li X., Gong L., Bao G., Fu Q., Chen S., Lin W., Shi H., Ma J., Liu X., Ma Q., Yao L. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer 2008, 8:303.
20. Ma J., Jin H., Wang H., Yuan J., Bao T., Jiang X., Zhang W., Zhao H., Yao L. Expression of NDRG2 in clear cell renal cell carcinoma. Biol. Pharm. Bull. 2008, 31:1316-1320.
21. Hu X.L., Liu X.P., Lin S.X., Deng Y.C., Liu N., Li X., Yao L.B. NDRG2 expression and mutation in human liver and pancreatic cancers. World J. Gastroenterol. 2004, 10:3518-3521.
22. Wang L., Liu N., Yao L., Li F., Zhang J., Deng Y., Liu J., Ji S., Yang A., Han H., Zhang Y., Zhang J., Han W., Liu X. NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell. Physiol. Biochem. 2008, 21:239-250.
23. Liu L., Ning X., Sun L., Zhang H., Shi Y., Guo C., Han S., Liu J., Sun S., Han Z., Wu K., Fan D. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008, 99:121-128.
24. Liu X., Hu X., Zhang J., Wang L., Zhang W., Liu X., Li F., Zhang Y., Yao L. Preparation and application of monoclonal antibody against hNDRG2. Appl. Biochem. Biotechnol. 2009, 152:306-315.
25. Tepel M., Roerig P., Wolter M., Gutmann D.H., Perry A., Reifenberger G., Riemenschneider M.J. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int. J. Cancer 2008, 123:2080-2086.
26. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(?Delta Delta C(T)) Method. Methods 2001, 25:402-408.
27. Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441.
28. Anoopkumar-Dukie S., Carey J.B., Conere T., O'sullivan E., van Pelt F.N., Allshire A. Resazurin assay of radiation response in cultured cells. Br. J. Radiol. 2005, 78:945-947.
29. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., Johnson R.S. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 2003, 23:359-369.
30. Piret J.P., Lecocq C., Toffoli S., Ninane N., Raes M., Michiels C. Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp. Cell Res. 2004, 295:340-349.
31. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
32. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., Seetharam S., Koons A., Hari D.M., Kufe D.W., Weichselbaum R.R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999, 59:3374-3378.
33. Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269:23757-23763.
34. Zhang X., Kon T., Wang H., Li F., Huang Q., Rabbani Z.N., Kirkpatrick J.P., Vujaskovic Z., Dewhirst M.W., Li C.Y. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004, 64:8139-8142.
35. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., Dewhirst M.W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8:99-110.
36. Williams K.J., Telfer B.A., Xenaki D., Sheridan M.R., Desbaillets I., Peters H.J., Honess D., Harris A.L., Dachs G.U., van der Kogel A., Stratford I.J. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 2005, 75:89-98.
37. Kim W.Y., Oh S.H., Woo J.K., Hong W.K., Lee H.Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res. 2009, 69:1624-1632.
38. Singh-Gupta V., Zhang H., Banerjee S., Kong D., Raffoul J.J., Sarkar F.H., Hillman G.G. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int. J. Cancer 2009, 124:1675-1684.
39. Nakamura M., Bodily J.M., Beglin M., Kyo S., Inoue M., Laimins L.A. Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology 2009, 387:442-448.
40. Zhang J., Liu J., Li X., Li F., Wang L., Zhang J., Liu X., Shen L., Liu N., Deng Y., Yang A., Han H., Zhao M., Yao L. The physical and functional interaction of NDRG2 with MSP58 in cells. Biochem. Biophys. Res. Commun. 2007, 352:6-11.